title: Intensified regimen for advanced head and neck squamous cell carcinomas.
abstract: OBJECTIVE
  To devise an intensified treatment regimen for patients with advanced, resectable head and neck squamous cell carcinomas.
  
  
  METHODS
  Phase I/II clinical trial consisting of perioperative cisplatin chemoradiotherapy, surgical resection, intraoperative radiotherapy, and postoperative cisplatin chemoradiotherapy.
  
  
  METHODS
  The Ohio State University Comprehensive Cancer Center, Columbus.
  
  
  METHODS
  Thirty-seven patients (median age, 63 years) with advanced oral cavity, oropharyngeal, or hypopharyngeal carcinomas.
  
  
  RESULTS
  The range of time at risk was 1 to 30 months (median, 21 months). Thirty of the 37 registered patients were analyzable; 11 have died (5 with distant metastases; 1 of lung carcinoma; and 5 were cancer-free); 2 experienced second primary tumors in the oral cavity (out of or adjacent to the previous radiotherapy portals). Treatment compliance was excellent (92%), morbidity was low, and excellent locoregional control was achieved.
  
  
  CONCLUSIONS
  The initial results are encouraging; the future strategy will intensify the systemic component of therapy based on results from concurrent laboratory studies.
authors.affiliation: Department of Otolaryngology, Arthur G. James Cancer Hospital and Research Institute, Ohio State University, Columbus, USA.
authors.forename: D E
authors.initials: DE
authors.lastname: Schuller
authors.forename: J C
authors.initials: JC
authors.lastname: Grecula
authors.forename: R A
authors.initials: RA
authors.lastname: Gahbauer
authors.forename: C
authors.initials: C
authors.lastname: Bauer
authors.forename: J L
authors.initials: JL
authors.lastname: Au
authors.forename: R E
authors.initials: RE
authors.lastname: Smith
authors.forename: J R
authors.initials: JR
authors.lastname: Haller
authors.forename: R E
authors.initials: RE
authors.lastname: Mountain
authors.forename: D C
authors.initials: DC
authors.lastname: Young
authors.forename: S
authors.initials: S
authors.lastname: Nag
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011879:Radiotherapy Dosage; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin